[Ca2+]i signaling vs. eNOS expression as determinants of NO output in uterine artery endothelium: relative roles in pregnancy adaptation and reversal by VEGF165.
Pregnancy is a time of greatly increased uterine blood flow to meet the needs of the growing fetus. Increased uterine blood flow is also observed in the follicular phase of the ovarian cycle. Simultaneous fura-2 and 4,5-diaminofluoresceine (DAF-2) imaging reveals that cells of the uterine artery endothelium (UA Endo) from follicular phase ewes produce marginally more nitric oxide (NO) in response to ATP than those from luteal phase. However, this is paralleled by changes in NO in response to ionomycin, suggesting this is solely due to higher levels of endothelial nitric oxide synthase (eNOS) protein in the follicular phase. In contrast, UA Endo from pregnant ewes (P-UA Endo) produces substantially more NO (4.62-fold initial maximum rate, 2.56-fold overall NO production) in response to ATP, beyond that attributed to eNOS levels alone (2.07-fold initial maximum rate, 1.93-fold overall with ionomycin). The ATP-stimulated intracellular free calcium concentration ([Ca(2+)](i)) response in individual cells of P-UA Endo comprises an initial peak followed by transient [Ca(2+)](i) bursts that are limited in the luteal phase, not altered in the follicular phase, but are sustained in pregnancy and observed in more cells. Thus pregnancy adaptation of UA Endo NO output occurs beyond the level of eNOS expression and likely through associated [Ca(2+)](i) cell signaling changes. Preeclampsia is a condition of a lack of UA Endo adaptation and poor NO production/vasodilation and is associated with elevated placental VEGF(165). While treatment of luteal NP-UA Endo and P-UA Endo with VEGF(165) acutely stimulates a very modest [Ca(2+)](i) and NO response, subsequent stimulation of the same vessel with ATP results in a blunted [Ca(2+)](i) and an associated NO response, with P-UA Endo reverting to the response of luteal NP-UA Endo. This demonstrates the importance of adaptation of cell signaling over eNOS expression in pregnancy adaptation of uterine endothelial function and further implicates VEGF in the pathophysiology of preeclampsia.
Perinatal Research Laboratories, Department of Obstetrics and Gynecology, University of Wisconsin, Madison, USA.
Fu-Xian
FX
Yi
Derek S
DS
Boeldt
Ronald R
RR
Magness
Ian M
IM
Bird
D000222:Adaptation, Physiological / Q000187:drug effects*; D000255:Adenosine Triphosphate / Q000494:pharmacology; D000818:Animals; D015220:Calcium Channels / Q000187:drug effects / Q000378:metabolism*; D002478:Cells, Cultured; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D005260:Female; D015759:Ionomycin / Q000494:pharmacology; D007476:Ionophores / Q000494:pharmacology; D009569:Nitric Oxide / Q000096:biosynthesis*; D052250:Nitric Oxide Synthase Type III / Q000096:biosynthesis / Q000378:metabolism*; D010920:Placenta / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism; D011225:Pre-Eclampsia / Q000188:drug therapy / Q000378:metabolism; D011247:Pregnancy; D012756:Sheep; D015398:Signal Transduction / Q000187:drug effects; D055988:Uterine Artery / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D042461:Vascular Endothelial Growth Factor A / Q000096:biosynthesis / Q000494:pharmacology*
D015220:Calcium Channels; D007476:Ionophores; D042461:Vascular Endothelial Growth Factor A; D009569:Nitric Oxide; D015759:Ionomycin; D000255:Adenosine Triphosphate; D052250:Nitric Oxide Synthase Type III
Am J Physiol Heart Circ Physiol. 2001 Apr;280(4):H1692-8
11247781
Am J Physiol Heart Circ Physiol. 2002 Dec;283(6):H2725-32
12388315
J Cell Sci. 2001 Mar;114(Pt 6):1229-35
11228166
Biochem Soc Trans. 2003 Dec;31(Pt 6):1171-7
14641020
J Soc Gynecol Investig. 1999 Jan-Feb;6(1):3-10
10065419
Am J Physiol Endocrinol Metab. 2010 Feb;298(2):E222-8
19920217
Endocrinology. 2001 Jul;142(7):3014-26
11416023
J Clin Endocrinol Metab. 2005 Jul;90(7):4299-308
15840747
Int J Dev Biol. 2010;54(2-3):331-9
19876820
Am J Physiol. 1997 Feb;272(2 Pt 2):R441-63
9124465
Endocrinology. 2006 May;147(5):2442-57
16455784
Endocrinology. 2000 Mar;141(3):1107-17
10698187
J Endocrinol. 2006 Aug;190(2):385-95
16899571
Biol Reprod. 2010 Jan;82(1):66-75
19741206
J Endocrinol. 2006 Aug;190(2):373-84
16899570
J Clin Endocrinol Metab. 1978 Jun;46(6):1007-10
122438
Biochem J. 2009 Jan 15;417(2):501-11
18816248
Am J Physiol Regul Integr Comp Physiol. 2005 Jan;288(1):R140-8
15297265
Endocrinology. 2003 Aug;144(8):3639-50
12865347
Cardiovasc Hematol Agents Med Chem. 2010 Apr;8(2):87-95
20184549
Biol Reprod. 2004 Jun;70(6):1886-94
14985241
Am J Physiol Regul Integr Comp Physiol. 2003 Feb;284(2):R245-58
12529278
Am J Physiol. 1997 Apr;272(4 Pt 2):H1730-40
9139957
Clin Chim Acta. 2010 Nov 11;411(21-22):1591-5
20659441